Exton firm advancing drug candidate to help 'butterfly children'
Fibrocell Science Inc., a Chester County gene and cell therapy company, is making progress on its experimental treatment to help “butterfly children.”
The Exton company’s lead drug candidate, FCX-007, is being developed to treat a condition known as recessive dystrophic epidermolysis bullosa (RDEB).
The rare skin disease afflicts an estimated 1,100 to 2,500 people, mostly children, nationwide. The condition prevents t he layers of skin from forming properly. As a result, pediatric patients…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: John George Source Type: news
More News: Children | Epidermolysis Bullosa | Genetics | Health Management | Pediatrics | Science | Skin